Ablynx NV plans to initiate end of Phase II meetings with US and European regulators shortly with a view to beginning a Phase III study by the end of next year following AbbVie Inc.'s decision not to opt in to a license for vobarilizumab in rheumatoid arthritis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?